ReviewF1000Research2018
Recent advances in understanding and managing retinal vein occlusions.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Mendelian randomization indicates a causal contribution of type 2 diabetes to retinal vein occlusion.Frontiers in endocrinology · 2023Pooled it
- Quantitative analysis of choroidal changes in retinal vein occlusion using ultra-widefield swept-source optical coherence tomography angiography.International ophthalmology · 2026Article
- Identifying the Involvement of Gut Microbiota in Retinal Vein Occlusion by Mendelian Randomization and Genetic Correlation Analysis.Translational vision science & technology · 2025Article
- Advances in the Clinical Use of Clopidogrel: A Review of Individualized Treatment Strategies and Monitoring Optimization Based on Genetic Polymorphisms.Pharmacogenomics and personalized medicine · 2025Review
- Review
- Evaluating the Efficacy of Conbercept and Dexamethasone Implants Sequentially in the Treatment of Refractory Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO): A One-Year Follow-Up Study.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Network-based inference of master regulators in epithelial membrane protein 2-treated human RPE cells.BMC genomic data · 2022Article
- Hemi-central retinal vein occlusion as a rare manifestation of the hypercoagulable state in COVID-19.BMJ case reports · 2021Article
- A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.Ophthalmology and therapy · 2020Article
- Simultaneous intravitreal dexamethasone and aflibercept for refractory macular edema secondary to retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2020Article
- Assessment of Spontaneous Retinal Arterial Pulsations in Acute Central Retinal Vein Occlusions.Journal of ophthalmology · 2020Article
- Effects of Common Thrombophilia Factor Mutations in Central Retinal Vein Occlusion.Beyoglu eye journal · 2019Article
- Long-term outcomes of intravitreous bevacizumab or tissue plasminogen activator or vitrectomy for macular edema due to branch retinal vein occlusion.Clinical ophthalmology (Auckland, N.Z.) · 2019Article
- Clopidogrel therapy in nonischemic central retinal vein occlusion: A case report and therapeutic insight.Oman journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal vein occlusions are the second most common form of retinal vascular disease. Previously, laser treatment for branch retinal vein occlusion and intravitreal triamcinolone acetonide for central retinal vein occlusion were the standard of care. Recent studies have demonstrated that anti-vascular endothelial growth factor (anti-VEGF) agents have a superior safety and efficacy profile for the treatment of both branch and central retinal vein occlusions. The use of wide-field fluorescein angiography has also allowed better visualization of the retinal periphery. Despite the better documentation of retinal non-perfusion, laser photocoagulation to the areas of non-perfusion does not seem to result in a reduction of macular edema or reduction in treatment burden and has been relegated to patients who develop rubeosis or neovascularization of the retina. More recently, several studies have demonstrated the use of a long-acting dexamethasone implant administered intravitreally or triamcinolone administered in the suprachoroidal space as a viable approach to treat retinal vein occlusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.